PAREXEL International Corp (PRXL)

per wallst tracker edwardowens

Earnings report last night. Poor report.

Blanket pick on the CRO market under the assumption that it will return to growth in 2010. This just seems like the right time to make this call (we'll see).

TMFHelical

Taking a flyer on this one - this company looks interesting in that it has a (noncyclical?) steady growth rate that is compelling versus its p/e ratio. I'm going with the PEG ratio here. The thing that can go wrong for a company like this is customer concentration or even customers taking business in house. I would love any comments on these topics anyone has.

Lagard in the current rally, holds value, right sector for a continuation of the bear.

Because I can bet the sector will win, without the risk of crappy management....Pfizer *cough cough*

Taking today's (1/27) 30% gain on this stock and going Thumbs Down for a few weeks.

So cheap.

Low Relative PE, good caps score, upcoming earnings not too bad decent lt growth prospects - bottom fishing.

Considerable backlog exists for the services of this clinical research and marketing company whose stock has taken an unjustified hit of late.

One of few stocks in the world that operates in an industry outside of the FIRE sector of economy (FIRE = Financial, Insurance & Real Estate).
In fact, not only does this company operate outside of FIRE, but it offers good future dividend potential, great valuation to earning potential, and is a great pick within its respective sector.



These are companies I'd put my money into right now rather than into residential real estate, apartment buildings, other stocks, commodities, or bonds. Few may fail, but just as many will quadruple within the next decade.


BUY.


bullish on nws, hnsn, prxl, aray, chp, navi, hero, bas, pcz, cybx, feic, ebay



These picks are within this CAPs account that is market neutral - all longs are offset by a short. All long & short picks are diversified across industries & world location to limit downside exposure. This CAPS account will maintain at the very least 20 picks and at the very most 80 picks. Picks will be ended in long/short pairs to remain neutral.

This stock has consistently outperformed the S&P 500 and seems to be undervalued due to the recent sell off. No debt makes them very attractive in this market.

Clinical research. 4 star.

Breakout today from cup-with-handle, right at confluence of 50-day and 200-day MAs

Biggest gainer in equity potential rank

it will keep growing

This stock is set to split in the middle of March. With $1 billion in sales, and anticipated earnings of almost 30% for both this year and next, PRXL will be a great investment.

Great sector to be in. Similar to an oil-service stock- you get all of the benefits with minimal risk. Easy outperform.

Parexel Intl. Corp, a bio/pharmaceutical srvcs. company, provides clincal research, medical communication srvcs, consulting and tech. products to medical industries worldwide, with a $1.55 B Market cap; its Diversified Svcs sector has been 16th best of 31 sectors the last 12 mos. at -5.6%. Zack's rank is a "2", PEG ratios of 1.15 and 0.91 for the next two years fwd show value left for price increasing on top of the 25.6% rise over the last six months. Earnings reported on 4/28/08; last two quarters it has averaged a +23.3 percent surprise and 25% year to year sales growth, to $943 million. Price/Sales ratio is now at 1.64 and this year's earnings est. have increased from 0.82 to 0.84. Current buy range of 27 - 27.75; short term target of $29.95; long term of $34.50 . Vector Vest currently rates them a "Buy" at 27.40 with a P/E of 16.21, and a value of 37.31, and a stop loss at 25.40. They just split 2 for 1 and now might back off a little after the run-up to the split and I am looking for a decent entry point.